Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.
2.

The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.

Chaudhry HM, Bruce AJ, Wolf RC, Litzow MR, Hogan WJ, Patnaik MS, Kremers WK, Phillips GL, Hashmi SK.

Biol Blood Marrow Transplant. 2016 Apr;22(4):605-16. doi: 10.1016/j.bbmt.2015.09.014. Epub 2015 Sep 26. Review.

3.

New developments in the prophylaxis and treatment of graft versus host disease.

Simpson D.

Expert Opin Pharmacother. 2001 Jul;2(7):1109-17. Review.

PMID:
11583062
4.

Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.

Minagawa K, Yamamori M, Katayama Y, Matsui T.

Int J Hematol. 2012 Jul;96(1):10-25. doi: 10.1007/s12185-012-1086-x. Epub 2012 May 17. Review.

PMID:
22592321
5.

Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?

Mussetti A, Greco R, Peccatori J, Corradini P.

Expert Rev Hematol. 2017 May;10(5):479-492. doi: 10.1080/17474086.2017.1318054. Epub 2017 May 5. Review.

PMID:
28395546
6.

Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation.

Woo M, Przepiorka D, Ippoliti C, Warkentin D, Khouri I, Fritsche H, Körbling M.

Bone Marrow Transplant. 1997 Dec;20(12):1095-8. Review.

7.

Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease--systematic review and meta-analysis.

Ram R, Yeshurun M, Vidal L, Shpilberg O, Gafter-Gvili A.

Leuk Res. 2014 Mar;38(3):352-60. doi: 10.1016/j.leukres.2013.12.012. Epub 2013 Dec 25. Review.

PMID:
24418750
8.

Prophylactic and therapeutic treatment of graft-versus-host disease in Japan.

Murata M.

Int J Hematol. 2015 May;101(5):467-86. doi: 10.1007/s12185-015-1784-2. Epub 2015 Apr 12. Review.

PMID:
25864188
9.

Current and emerging strategies for the prevention of graft-versus-host disease.

Choi SW, Reddy P.

Nat Rev Clin Oncol. 2014 Sep;11(9):536-47. doi: 10.1038/nrclinonc.2014.102. Epub 2014 Jun 24. Review.

10.

Acute Graft Versus Host Disease: A Comprehensive Review.

Nassereddine S, Rafei H, Elbahesh E, Tabbara I.

Anticancer Res. 2017 Apr;37(4):1547-1555. Review.

PMID:
28373413
11.

Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Servais S, Beguin Y, Delens L, Ehx G, Fransolet G, Hannon M, Willems E, Humblet-Baron S, Belle L, Baron F.

Expert Opin Investig Drugs. 2016 Aug;25(8):957-72. doi: 10.1080/13543784.2016.1182498. Epub 2016 May 9. Review.

PMID:
27110922
12.

Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Nassar A, Elgohary G, Elhassan T, Nurgat Z, Mohamed SY, Aljurf M.

J Transplant. 2014;2014:980301. doi: 10.1155/2014/980301. Epub 2014 Oct 27. Review.

13.

Graft-versus-host disease: why have we not made more progress?

Jaglowski SM, Devine SM.

Curr Opin Hematol. 2014 Mar;21(2):141-7. doi: 10.1097/MOH.0000000000000026. Review.

14.

First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA.

Biol Blood Marrow Transplant. 2012 Aug;18(8):1150-63. doi: 10.1016/j.bbmt.2012.04.005. Epub 2012 Apr 14. Review.

15.

Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?

Storb R, Antin JH, Cutler C.

Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S18-27. doi: 10.1016/j.bbmt.2009.10.016. Epub 2009 Oct 24. Review.

16.

New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease.

Lutz M, Mielke S.

Br J Clin Pharmacol. 2016 Nov;82(5):1171-1179. doi: 10.1111/bcp.13022. Epub 2016 Jun 22. Review.

PMID:
27245261
17.

A risk-adapted approach to acute GVHD treatment: are we there yet?

Holtan SG, MacMillan ML.

Bone Marrow Transplant. 2016 Feb;51(2):172-5. doi: 10.1038/bmt.2015.261. Epub 2015 Nov 9. Review.

PMID:
26551780
18.

Effect of methotrexate on bone and wound healing.

Pountos I, Giannoudis PV.

Expert Opin Drug Saf. 2017 May;16(5):535-545. doi: 10.1080/14740338.2017.1310839. Epub 2017 Mar 29. Review.

PMID:
28332422
19.

Stem cell transplantation as a dynamical system: are clinical outcomes deterministic?

Toor AA, Kobulnicky JD, Salman S, Roberts CH, Jameson-Lee M, Meier J, Scalora A, Sheth N, Koparde V, Serrano M, Buck GA, Clark WB, McCarty JM, Chung HM, Manjili MH, Sabo RT, Neale MC.

Front Immunol. 2014 Dec 3;5:613. doi: 10.3389/fimmu.2014.00613. eCollection 2014. Review.

Supplemental Content

Support Center